Zacks Research Upgrades Eupraxia Pharmaceuticals (NASDAQ:EPRX) to “Hold”

Eupraxia Pharmaceuticals (NASDAQ:EPRX) was upgraded by stock analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued on Thursday,Zacks.com reports.

A number of other research analysts also recently issued reports on EPRX. HC Wainwright reiterated a “buy” rating and set a $11.00 target price on shares of Eupraxia Pharmaceuticals in a research report on Monday, May 4th. William Blair started coverage on shares of Eupraxia Pharmaceuticals in a research report on Monday, March 23rd. They set an “outperform” rating on the stock. Wall Street Zen upgraded shares of Eupraxia Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research note on Tuesday, April 21st. Finally, Cantor Fitzgerald boosted their price target on shares of Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the company an “overweight” rating in a research note on Thursday, January 15th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $15.00.

Eupraxia Pharmaceuticals Stock Down 0.3%

Eupraxia Pharmaceuticals stock opened at $7.45 on Thursday. Eupraxia Pharmaceuticals has a 12-month low of $3.67 and a 12-month high of $9.32. The firm’s fifty day moving average is $7.38 and its 200 day moving average is $7.22. The company has a market capitalization of $450.20 million, a PE ratio of -7.23 and a beta of 1.19.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last released its earnings results on Thursday, March 19th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.21). Sell-side analysts expect that Eupraxia Pharmaceuticals will post -0.74 EPS for the current fiscal year.

Institutional Trading of Eupraxia Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vivo Capital LLC bought a new stake in Eupraxia Pharmaceuticals during the 3rd quarter valued at $7,965,000. Ally Bridge Group NY LLC bought a new stake in Eupraxia Pharmaceuticals during the 3rd quarter valued at $5,398,000. Ikarian Capital LLC bought a new stake in Eupraxia Pharmaceuticals during the 4th quarter valued at $4,606,000. Squadron Capital Management LLC bought a new stake in shares of Eupraxia Pharmaceuticals in the 4th quarter worth $3,775,000. Finally, Velan Capital Investment Management LP bought a new stake in shares of Eupraxia Pharmaceuticals in the 3rd quarter worth $2,077,000.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.